Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
Guntram Schernthaner,1 Sarah Jarvis,2 Chaim Lotan,3 Martin Prázný,4 Christoph Wanner,5 Thomas C Wascher6 1Department of Medicine, Rudolfstiftung Hospital, Vienna, Austria; 2Richford Gate Medical Practice, London, UK; 3Cardiovascular Division, Heart Institute, Hadassah-Hebrew U...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-01-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/advances-in-the-management-of-cardiovascular-risk-for-patients-with-ty-peer-reviewed-article-TCRM |
| _version_ | 1818928618024206336 |
|---|---|
| author | Schernthaner G Jarvis S Lotan C Prázný M Wanner C Wascher TC |
| author_facet | Schernthaner G Jarvis S Lotan C Prázný M Wanner C Wascher TC |
| author_sort | Schernthaner G |
| collection | DOAJ |
| description | Guntram Schernthaner,1 Sarah Jarvis,2 Chaim Lotan,3 Martin Prázný,4 Christoph Wanner,5 Thomas C Wascher6 1Department of Medicine, Rudolfstiftung Hospital, Vienna, Austria; 2Richford Gate Medical Practice, London, UK; 3Cardiovascular Division, Heart Institute, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; 4First Faculty of Medicine, Charles University, Prague, Czech Republic; 5Department of Medicine, University Hospital, Würzburg, Germany; 6First Medical Department, Hanusch-Krankenhaus, Vienna, Austria Abstract: Diabetes is a global health emergency projected to affect 642 million people by 2040. Type 2 diabetes (T2D) represents 90% of diabetes cases and is associated with a range of cardiovascular (CV) risk factors that are more than double the incidence of CV disease and significantly increase mortality rates. Diabetes treatments have typically focused on improving glycemic control but their effect on CV outcomes has remained uncertain. In 2008, the US Food and Drug Administration (FDA) looked to address this knowledge gap and mandated CV outcome trials (CVOTs) for all new antidiabetic therapies. In 2015, EMPA-REG OUTCOME® became the first CVOT to present results for a sodium/glucose cotransporter 2 (SGLT2; also known as SLC5A2) inhibitor, empagliflozin. Subsequently, a regional meeting of the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D) brought together a respected faculty of international experts and 150 physicians from 14 countries to discuss the current unmet medical needs of patients with T2D, the results from the EMPA-REG OUTCOME study and the implications of these results for clinical practice. This article summarizes the current scientific evidence and the discussions that took place at the ACROSS T2D regional meeting, which was held in Vienna, Austria, on May 30, 2016. Keywords: type 2 diabetes, cardiovascular risk, SGLT2 inhibitor, CVOTs, empagliflozin |
| first_indexed | 2024-12-20T03:31:46Z |
| format | Article |
| id | doaj.art-780d6965c5de457da43e280bebe96a26 |
| institution | Directory Open Access Journal |
| issn | 1178-203X |
| language | English |
| last_indexed | 2024-12-20T03:31:46Z |
| publishDate | 2017-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-780d6965c5de457da43e280bebe96a262022-12-21T19:54:59ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2017-01-01Volume 13697930863Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 DiabetesSchernthaner GJarvis SLotan CPrázný MWanner CWascher TCGuntram Schernthaner,1 Sarah Jarvis,2 Chaim Lotan,3 Martin Prázný,4 Christoph Wanner,5 Thomas C Wascher6 1Department of Medicine, Rudolfstiftung Hospital, Vienna, Austria; 2Richford Gate Medical Practice, London, UK; 3Cardiovascular Division, Heart Institute, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; 4First Faculty of Medicine, Charles University, Prague, Czech Republic; 5Department of Medicine, University Hospital, Würzburg, Germany; 6First Medical Department, Hanusch-Krankenhaus, Vienna, Austria Abstract: Diabetes is a global health emergency projected to affect 642 million people by 2040. Type 2 diabetes (T2D) represents 90% of diabetes cases and is associated with a range of cardiovascular (CV) risk factors that are more than double the incidence of CV disease and significantly increase mortality rates. Diabetes treatments have typically focused on improving glycemic control but their effect on CV outcomes has remained uncertain. In 2008, the US Food and Drug Administration (FDA) looked to address this knowledge gap and mandated CV outcome trials (CVOTs) for all new antidiabetic therapies. In 2015, EMPA-REG OUTCOME® became the first CVOT to present results for a sodium/glucose cotransporter 2 (SGLT2; also known as SLC5A2) inhibitor, empagliflozin. Subsequently, a regional meeting of the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D) brought together a respected faculty of international experts and 150 physicians from 14 countries to discuss the current unmet medical needs of patients with T2D, the results from the EMPA-REG OUTCOME study and the implications of these results for clinical practice. This article summarizes the current scientific evidence and the discussions that took place at the ACROSS T2D regional meeting, which was held in Vienna, Austria, on May 30, 2016. Keywords: type 2 diabetes, cardiovascular risk, SGLT2 inhibitor, CVOTs, empagliflozinhttps://www.dovepress.com/advances-in-the-management-of-cardiovascular-risk-for-patients-with-ty-peer-reviewed-article-TCRMType 2 diabetesCardiovascular riskSGLT2 inhibitorCVOTsEmpagliflozin |
| spellingShingle | Schernthaner G Jarvis S Lotan C Prázný M Wanner C Wascher TC Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes Therapeutics and Clinical Risk Management Type 2 diabetes Cardiovascular risk SGLT2 inhibitor CVOTs Empagliflozin |
| title | Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes |
| title_full | Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes |
| title_fullStr | Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes |
| title_full_unstemmed | Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes |
| title_short | Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes |
| title_sort | advances in the management of cardiovascular risk for patients with type 2 diabetes perspectives from the academy for cardiovascular risk outcomes and safety studies in type 2 diabetes |
| topic | Type 2 diabetes Cardiovascular risk SGLT2 inhibitor CVOTs Empagliflozin |
| url | https://www.dovepress.com/advances-in-the-management-of-cardiovascular-risk-for-patients-with-ty-peer-reviewed-article-TCRM |
| work_keys_str_mv | AT schernthanerg advancesinthemanagementofcardiovascularriskforpatientswithtype2diabetesperspectivesfromtheacademyforcardiovascularriskoutcomesandsafetystudiesintype2diabetes AT jarviss advancesinthemanagementofcardiovascularriskforpatientswithtype2diabetesperspectivesfromtheacademyforcardiovascularriskoutcomesandsafetystudiesintype2diabetes AT lotanc advancesinthemanagementofcardiovascularriskforpatientswithtype2diabetesperspectivesfromtheacademyforcardiovascularriskoutcomesandsafetystudiesintype2diabetes AT praznym advancesinthemanagementofcardiovascularriskforpatientswithtype2diabetesperspectivesfromtheacademyforcardiovascularriskoutcomesandsafetystudiesintype2diabetes AT wannerc advancesinthemanagementofcardiovascularriskforpatientswithtype2diabetesperspectivesfromtheacademyforcardiovascularriskoutcomesandsafetystudiesintype2diabetes AT waschertc advancesinthemanagementofcardiovascularriskforpatientswithtype2diabetesperspectivesfromtheacademyforcardiovascularriskoutcomesandsafetystudiesintype2diabetes |